Make use of the great translatability of our 3D organoid models which show unprecedented patient response predictivity. Benefit from faster development and enhanced scalability of organoids. Model and mirror patient population diversity via screening multiple tumor organoid models simultaneously, and access both tumor and healthy organoids to evaluate in vitro data with clinically relevant drug potency and efficacy as well as off target effects.
Preclinical oncology drug development and validation services using unique organoid models developed using IP-protected Hubrecht Organoid Technology (HUB) protocols, as well as HUB’s biobank of already established patient-derived organoids (PDOs)
Large-scale screens: Select models, and evaluate efficacy and multi-drug combination strategies
Efficacy and viability quantification: Identify responder and non-responder tumor models. Leverage high content services to produce highly comprehensive morphology readouts in both 2D and 3D models. Use multifactorial data for downstream lead ID and decision-making
HCI-based phenotype screening: Phenotypical screen up to thousands of compounds. Layer and score drug effects with image mediated screens
Immunotherapy assessment: Benefit from the only immuno- oncology platform incorporating patient-relevant 3D in vitro models co-cultured with non-autologous immune cells
Simplify your model selection with collated mutational and gene expression profiles for tumor organoid models with this searchable organoid biobank database of PDX-derived organoid (PDXO) tumor models and patient-derived organoids (PDO) organoid models
Get deeper insights with a suite of powerful 3D in vitro imaging-based assays that recapitulate and quantify complex human biology in a robust and high-throughput imaging platform. Follow up with assisted high content analysis study options.
Expand into immunotherapeutic assessment using the only immuno-oncology platform incorporating patient-relevant 3D in vitro models co-cultured with non-autologous immune cells